Introduction: Lung cancer is one of the most common cancers with high mortality rate because of the late diagnosis. The present study aimed to quantitatively measure the C-X-C Motif Chemokine Ligand 5 (CXCL5) gene expression level in tissue samples of lung cancer patients to investigate its value as a biomarker during lung cancer diagnosis and screening.
Materials and Methods: Tissue samples were collected from 30 patients. Total RNA was extracted from tumor and normal tissues of patients. The rate of CXCL5 gene expression was initially measured in A549 cell line and next, the expression level of this gene in tumor tissue samples of patients suffering from Non-Small Cell Lung Cancer was compared to the normal lung tissue of the same patients.
Results: The results demonstrated significant increase of CXCL5 gene expression in cancer samples compared to normal tissues of the same samples. The increase was 5.8 fold for cancerous tissues in comparison with normal tissues (P=0.03). There was no difference between the tumor type (adenocarcinoma, squamous cell carcinoma) and average CXCL5 gene expression rate (P=0.09). In cancerous samples, the expression level of CXCL5 was higher in men compared with those of women (P=0.04). There was no relationship between the change of gene expression and the age of the patients (p=0.08).
Conclusion: Based on the results, it can be concluded that the quantitative expression level of CXCL5 in lung cancer patients could be used as a biomarker to screen lung cancer samples, regardless of age of patients and tumor type. However, it can discriminate the stage of tumor.
Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011; 365(5):395–409.
Kang SM, Sung HJ, Ahn JM, Park JY, Lee SY, Park CS et al. The Haptoglobin β chain as a supportive biomarker for human lung cancers. Mol Biosyst 2011; 7(4):1167–75.
Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010; 363(18):1693–703.
Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002; 2(8):563–72.
Kawamura M, Toiyama Y, Tanaka K, Saigusa S, Okugawa Y, Hiro J et al. CXCL5, a promoter of cell proliferation, migration and invasion, is a novel serum prognostic marker in patients with colorectal cancer. Eur J Cancer 2012; 48(14):2244–51.
Kuo PL, Huang MS, Hung JY, Chou S-H, Chiang SY, Huang YF et al. Synergistic effect of lung tumor-associated dendritic cell-derived HB-EGF and CXCL5 on cancer progression. Int J Cancer 2014; 135(1):96–108.
Wong YF, Cheung TH, Lo KWK, Yim SF, Siu NSS, Chan SCS et al. Identification of molecular markers and signaling pathway in endometrial cancer in Hong Kong Chinese women by genome-wide gene expression profiling. Oncogene 2007; 26(13):1971.
Li A, King J, Moro A, Sugi MD, Dawson DW, Kaplan J et al. Overexpression of CXCL5 is associated with poor survival in patients with pancreatic cancer. Am J Pathol 2011; 178(3):1340–9.
Zhou S-L, Dai Z, Zhou Z-J, Wang XY, Yang GH, Wang Z et al. Overexpression of CXCL5 mediates neutrophil infiltration and indicates poor prognosis for hepatocellular carcinoma. Hepatology 2012; 56(6):2242–54.
Walz A, Roger B, Car B, Baggiolini M, Kunkel SL, Strieter RM. Structure and neutrophil-activating properties of a novel inflammatory peptide (ENA-78) with homology to interleukin 8. Journal of experimental medicine 1991; 174(6):1355–62.
Saurer L, Reber P, Schaffner T, Büchler MW, Buri C, Kappeler A et al. Differential expression of chemokines in normal pancreas and in chronic pancreatitis. Gastroenterology 2000; 118(2):356–67.
Imaizumi T, Albertine KH, Jicha DL, McIntyre TM, Prescott SM, Zimmerman GA. Human endothelial cells synthesize ENA-78: Relationship to IL-8 and to signaling of PMN adhesion. Am J Respir Cell Mol Biol 1997; 17(2):181–92.
Ruffini PA, Morandi P, Cabioglu N, Altundag K, Cristofanilli M. Manipulating the chemokine-chemokine receptor network to treat cancer. Cancer 2007; 109(12):2392–404.
Xu X, Huang P, Yang B, Wang X, Xia J. Roles of CXCL5 on migration and invasion of liver cancer cells. J Transl Med 2014; 12:193.
Kowalczuk O, Burzykowski T, Niklinska WE, Kozlowski M, Chyczewski L, Niklinski J. CXCL5 as a potential novel prognostic factor in early stage non-small cell lung cancer: Results of a study of expression levels of 23 genes. Tumour Biol 2014; 35(5):4619–28.
Põld M, Zhu LX, Sharma S, Burdick MD, Lin Y, Lee PPN et al. Cyclooxygenase-2-dependent expression of angiogenic CXC chemokines ENA-78/CXC Ligand (CXCL) 5 and interleukin-8/CXCL8 in human non-small cell lung cancer. Cancer Res 2004; 64(5):1853–60.
Rowland KJ, Diaz-Miron J, Guo J, Erwin CR, Mei J, Worthen GS et al. CXCL5 is required for angiogenesis, but not structural adaptation after small bowel resection. J Pediatr Surg 2014; 49(6):976-80; discussion 980.
Zhu X, Qiao Y, Liu W, Wang W, Shen H, Lu Y et al. CXCL5 is a potential diagnostic and prognostic marker for bladder cancer patients. Tumour Biol 2016; 37(4):4569–77.
Miyazaki H, Patel V, Wang H, Edmunds RK, Gutkind JS, Yeudall WA. Down-regulation of CXCL5 inhibits squamous carcinogenesis. Cancer Res 2006; 66(8):4279–84.
Qiu Y, Zhu J, Bandi V, Guntupalli KK, Jeffery PK. Bronchial mucosal inflammation and upregulation of CXC chemoattractants and receptors in severe exacerbations of asthma. Thorax 2007; 62(6):475–82.
Chen J, Wang T, Dai L, Wen F. Cigarette smoking induced elevated CXCL5 levels in BALF and plasma of patients with COPD. In: Airway Cell Biology and Immunopathology: European Respiratory Society; 2018. PA4268.
Balamayooran G, Batra S, Cai S, Mei J, Worthen GS, Penn AL et al. Role of CXCL5 in leukocyte recruitment to the lungs during secondhand smoke exposure. Am J Respir Cell Mol Biol 2012; 47(1):104–11.
Duffy MJ. Clinical uses of tumor markers: A critical review. Crit Rev Clin Lab Sci 2001; 38(3):225–62.